This medication is used across three primary therapeutic domains. The core domain is generally used for the prevention of pregnancy for women of childbearing potential. Additionally, it is applied across domains where additional symptomatic support is needed, relevant in conditions characterized by periods of heightened symptoms.

---

What YAZ (Oral) Treats: Main Uses and Benefits

The medication is commonly used to help address symptoms across three therapeutic domains: symptom management related to reproductive health, severe symptoms of Premenstrual Dysphoric Disorder (PMDD), and moderate acne vulgaris.

In clinical settings that involve acute or unstable symptom patterns, the medication is relevant for easing challenging symptoms that interfere with daily comfort. It may assist with maintaining a sense of stability and supports general well-being during symptomatic periods.

Contraception, PMDD, and Acne Symptom Support

The main therapeutic purpose is to offer primary contraception and generally assists with maintaining functional stability in reproductive health. It is also used for managing the menstrual cycle, and may contribute to easing the volume of menstrual flow while potentially assisting with managing symptoms related to painful menstruation (dysmenorrhea). In common real-world scenarios, it helps address pronounced emotional and physical symptom clusters associated with PMDD and is relevant in contexts involving symptom management for moderate acne vulgaris.

Quick Fact: Support for Severe Cyclical Mood Symptoms and Symptoms of Moderate Acne Vulgaris

Who Can and Cannot Use YAZ (Oral)?

Official regulatory information defines the eligible population and conditions under which the medicine must not be used.

Eligibility Scope

Classification	Population or Condition
Allowed Use	Females of reproductive potential who have achieved menarche.
Contraindicated	Women who are pregnant; smokers over 35 years of age.
Not Recommended	Women who are breastfeeding; use is not recommended less than four weeks after delivery.

Conditions That Prohibit Use (Contraindications)

The medicine must not be used by individuals with a current or history of venous or arterial thrombotic diseases (e.g., deep venous thrombosis, stroke, myocardial infarction) or an established hereditary/acquired clotting predisposition. Use is also prohibited in cases of adrenal insufficiency, severe renal impairment, or severe hepatic disease (including liver tumors) until liver function normalizes.

Additionally, the medicine is contraindicated for women with known or suspected hormone-sensitive cancers (such as breast cancer), migraine with focal neurological symptoms, severe hypertension, diabetes with vascular symptoms, or severe dyslipoproteinaemia.

Interactions with other medicines and products

The interaction profile for this product is structured by documented changes to hormone exposure and the specific pharmacodynamic property of Drospirenone.

Category
Formal Contraindicated Combinations
Co-administration with certain Hepatitis C drug combinations (Ombitasvir, Paritaprevir/Ritonavir, with or without Dasabuvir) is strictly prohibited due to the officially documented risk of elevated liver enzymes (ALT).
Interactions Affecting Hormone Exposure
Enzyme Inducers, such as Rifampin and certain anticonvulsants (e.g., Carbamazepine, Phenytoin), may reduce the plasma concentration of the contraceptive hormones, thereby potentially diminishing contraceptive effectiveness. The herbal product St. John’s Wort is also documented as a substance that may decrease effectiveness.
Strong CYP3A4 Inhibitors, such as Ketoconazole, are documented to significantly increase the systemic exposure (AUC) of the progestin component, Drospirenone.
Pharmacodynamic Risk
Drospirenone's antimineralocorticoid activity presents a pharmacodynamic risk of hyperkalemia when co-administered with other potassium-raising medications. These include Potassium-sparing diuretics (e.g., Spironolactone, Triamterene), ACE Inhibitors, ARBs, and chronic daily use of NSAIDs.
Required Monitoring and Restrictions
The official prescribing information mandates checking serum potassium concentration during the first treatment cycle for women on long-term treatment with potassium-raising medications. The product is also contraindicated in patients with severe renal impairment or hepatic disease due to increased interaction-related risks in these populations.

---

The regulatory documents define the product's interaction structure primarily through two critical axes: pharmacokinetic interactions that alter hormone plasma exposure and a specific pharmacodynamic interaction related to potassium homeostasis. This structure determines which combinations are formally contraindicated and mandates specific monitoring procedures for other clinically significant co-administered agents, strictly as written in the official prescribing information.

Central Regulation of the Reproductive Cycle

YAZ primarily functions by modulating the Hypothalamic-Pituitary-Ovarian (HPO) axis through continuous, suppressed levels of synthetic hormones. This mechanism involves a negative feedback loop on the brain, preventing the release of FSH and LH, which are necessary to trigger the final maturation and release of an egg. This suppression of upstream signaling is the core pathway leading to the inhibition of ovulation (anovulation).

---

Localized Effects on Cervical and Uterine Environments

The hormonal components also exert local influence on peripheral reproductive tissues. The progestin Drospirenone modifies the cervical mucus, causing it to thicken and become less permeable to sperm. Concurrently, the pill alters the structure of the endometrium (uterine lining), making it less receptive to implantation. These peripheral changes serve as important secondary mechanistic cascades which contribute to the cumulative biological consequence.

---

Unique Anti-Mineralocorticoid and Anti-Androgenic Activity

The specific progestin in YAZ, Drospirenone, acts as an antagonist on the Mineralocorticoid Receptor (MR) and Androgen Receptors (AR), a mechanism distinct from the anovulatory action. Blocking the MR influences pathways regulating fluid and electrolyte balance, while blocking the AR alters signaling sequences regulated by androgens, influencing downstream processes regulated by these receptor systems.

Official Administration Guidelines

Entity	Instruction
Route of administration	Oral only (taken by mouth).
Dosing schedule	One tablet taken daily for 28 consecutive days. The regimen consists of 24 active tablets (3 mg drospirenone/0.02 mg ethinyl estradiol) followed by 4 inactive tablets.
Timing in relation to meals	May be taken with or without food. Taking it after the evening meal or at bedtime is specified in the labeling.
Age-group administration rules	Indicated for use in females at least 14 years old who have begun menstruation.

---

Resulting Procedural Structure

The administration of YAZ is defined by a continuous, cyclic pattern that must be followed precisely at the same time each day. The official procedural sequence begins with two specific options for starting the first pack: the Day 1 Start (first day of the menstrual period) or the Sunday Start (the first Sunday after the start of the period).

Official step sequence:

• Active Period: Take one active tablet daily for 24 consecutive days, following the order directed on the blister pack.
• Inactive Period: Take one inactive tablet daily for the subsequent 4 consecutive days.
• Continuous Cycling: A new 28-day pack must be started on the day immediately following the last tablet of the previous pack, ensuring no gap in daily tablet intake.

Missed-dose management: Detailed rules exist for managing missed active and inactive tablets, which must be strictly followed to maintain the administration pattern. A non-hormonal barrier method is advised for the first seven days if the tablet is started later than the first day of the menstrual cycle.

Connection to the overall use protocol:

This required continuous, long-term pattern of daily oral intake is structured by the specific 24-day active followed by 4-day inactive cyclic schedule. This precise regimen dictates the necessary frequency, timing, and sequence of tablets, establishing the standardized approach for using the medication as outlined in standardized guidelines.

Research evidence / Overview of Studies for YAZ (Oral)

---

Evidence for use in Preventing Pregnancy (Contraception)

Research exploring YAZ (drospirenone/ethinyl estradiol) involves foundational pivotal efficacy studies and comparative randomized controlled trials (RCTs) in healthy women of childbearing potential. The primary outcome was the Pearl Index, and findings described observed incidence rates of pregnancy that were low within the trial parameters. Limited information is available for long-term outcomes beyond the typical one-year follow-up, and data for certain groups (e.g., higher Body Mass Index) remain insufficient.

---

Evidence for use in Managing Premenstrual Dysphoric Disorder (PMDD)

Evidence relies on two pivotal, placebo-controlled crossover trials in women diagnosed with PMDD. Studies measured changes in the severity of premenstrual symptoms, and findings indicate that symptom severity scores measured lower in subjects using the combination compared to those using a placebo. Research so far indicates that the effectiveness has not been reported for use extending beyond three menstrual cycles.

---

Evidence for use in Treating Moderate Acne Vulgaris

The research base includes two intermediate-term, placebo-controlled trials in females 14 years and older with moderate acne vulgaris. Studies monitored changes in lesion counts and used the ISGA scale to assess skin condition. Data describe patterns related to lesion counts measured lower when compared to placebo over the six-month study period. Data for treating severe acne are still emerging.

---

Long-term Studies and Durability of Reported Outcomes

Research examining contraceptive use typically explored outcomes for up to one year. However, for PMDD (three cycles) and moderate acne (six cycles), limited information is available for long-term outcomes and the continued observation of patterns beyond these initial follow-up durations. Research so far indicates that the follow-up durations were limited.

---

Evidence in Special Populations

Research indicates that the results apply only to the populations studied. Trial protocols often excluded women with certain comorbidities or a high Body Mass Index, meaning that data for these certain groups remain insufficient and specific subgroup findings are uncertain.

---

What Remains Uncertain and Research Gaps

Key evidence gaps include the limited information available for long-term outcomes for the PMDD and acne indications. Studies comparing this specific combination against other treatments are limited, and data for certain subgroups remain insufficient, highlighting what is still uncertain about this combination product.

Common questions about YAZ (Oral) (FAQ)

---

Q: Does YAZ cause weight gain in most people?

According to the official Patient Package Insert, weight gain is listed as one of the common side effects reported by women using oral contraceptives.

Q: Are there different versions or generics of YAZ available?

Yes, the active ingredients in YAZ (drospirenone and ethinyl estradiol) are available in multiple generic formulations. These generics have been approved by regulatory bodies, such as the FDA, for use.

Q: Are there any common foods or drinks that interact with YAZ?

The official interaction profile describes potential interactions with certain foods and beverages. Grapefruit and Grapefruit Juice may increase the blood levels of the drospirenone component, and the ethinyl estradiol component may increase the blood levels of caffeine.

Q: How quickly does YAZ start to work for its main purpose?

Official guidance on starting the medication specifies that if the daily regimen is not initiated on the first day of the menstrual period (Day 1 Start), an additional barrier method of non-hormonal contraception is required for the first 7 days of the first cycle. This is described to help ensure contraceptive effectiveness during the initial period.

Q: Is YAZ a low-dose oral contraceptive?

The estrogen component in YAZ, ethinyl estradiol, is 0.02 mg (or 20 mu g). According to general medical classification standards, combined oral contraceptives that contain le 35 mu g of ethinyl estradiol are often characterized as low-dose formulations.

Q: What non-prescription medications or supplements should I ask about before taking YAZ?

Regulatory documents indicate potential interactions with certain non-prescription items. The herbal supplement St. John’s Wort may reduce the drug's effectiveness. Also, chronic daily use of common pain relievers like Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may increase the risk of elevated potassium levels when used with this medication.

Q: What is the importance of taking the placebo pills in the YAZ pack?

The blister pack includes 4 inactive (placebo) tablets as part of the 28-day regimen. While these pills do not contain hormones, taking them helps maintain the required continuous daily routine of pill-taking, which is an important procedural step for consistent use.

Q: Does YAZ interact with antibiotics generally?

Official warnings mention that some antibiotics, such as the enzyme inducer Rifampin, can reduce YAZ's effectiveness. The Patient Information Leaflet also notes that other antibiotics may potentially reduce the effect of the estrogen component in some women.

Q: Is it normal to feel nauseous when first starting YAZ?

Nausea and vomiting are listed as frequent common side effects of the pill. According to the Patient Package Insert, these initial effects, particularly nausea, may subside within the first three months of use as the body adjusts to the medication.

Q: What is meant by the '4-day hormone-free interval' with YAZ?

This term refers to the 4 consecutive days within the 28-day cycle during which the patient takes the inactive (placebo) tablets. During this time, the body is not receiving the active hormones, which is when withdrawal bleeding typically occurs.

Q: Does the efficacy of YAZ change over time?

Studies examining the therapeutic effects of the drug for conditions like PMDD and acne have limited information available for long-term outcomes beyond the initial study follow-up periods. The durability of reported outcomes past these initial periods is not fully established in the research evidence.

Q: Is the hormone combination in YAZ considered unique?

The combination is defined by the specific progestin component, drospirenone, which possesses certain anti-mineralocorticoid and anti-androgenic activities. These actions differentiate its properties from progestins found in many other combined oral contraceptives.

Q: Can YAZ cause changes in vision?

Regulatory documents list sudden vision loss or blurred vision as a potential serious adverse event associated with the use of the drug. Additionally, less serious changes like difficulty wearing contact lenses are noted as a common side effect.

Q: What is the risk of an allergic reaction to YAZ?

The medication is contraindicated if a woman is hypersensitive (allergic) to the active ingredients or any of the other components. A severe allergic reaction is listed among the serious potential adverse effects documented in official information.

Q: Are there any warnings about YAZ use before surgery?

Official warnings state that discontinuation of combined oral contraceptive use is required before elective surgery (at least four weeks in advance). This precaution is due to the documented increased risk of blood clots until two weeks after complete re-mobilization.

Q: Can YAZ affect cholesterol levels?

The use of the medication may have carbohydrate and lipid metabolic effects, according to the drug label. The drug label describes that monitoring of lipid levels is mandated for women with uncontrolled dyslipidemia, and severe dyslipoproteinaemia is a formal contraindication.

Q: Is YAZ approved by the FDA for all its uses in all countries?

The medication requires separate marketing authorization for its uses in different countries. Regulatory records confirm that its authorization status and approved indications may vary across different markets compared to the US FDA.

How to Store and Dispose of YAZ (Oral)?

Official regulatory documents establish specific conditions for the storage and disposal of this medication to ensure its integrity and safety.

Storage Requirements

YAZ (Oral) must be stored at a controlled room temperature, typically between 68 F and 77 F (20 C and 25 C). The medication must be protected from both light and excess moisture; for this reason, storage in a bathroom is prohibited. The product must remain in its original container with the lid tightly closed.

Handling and Child Safety

As officially classified by some government sources as a hazardous drug (NIOSH Group 2), specific precautions, such as using gloves, should be observed if the tablets are manipulated. It is mandatory to store the medication out of the sight and reach of children, in a safe, secured location.

Disposal Rules

Unneeded medication must never be flushed down the toilet or poured into a drain. Disposal should be carried out through an authorized medicine take-back program. Consult a pharmacist regarding community take-back options.